Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines

Vaccine

Volumn 28, Issue 6, 2010, Pages 1547-1557

  Wang, Zhongde ^a   Martinez, Joy ^a   Zhou, Wendi ^a   La Rosa, Corinna ^a   Srivastava, Tumul ^a   Dasgupta, Anindya ^a   Rawal, Ravindra ^a   Li, Zhongqui ^a   Britt, William J ^b   Diamond, Don ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Cellular immunity; Herpesvirus; Modified Vaccinia Ankara; Poxvirus; Vaccine

Indexed keywords

MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VACCINE H5;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GENE DELETION; GENE INSERTION; GENETIC ENGINEERING; GENETIC STABILITY; GENETIC TRANSCRIPTION; IMMUNOGENICITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

ANIMALS; DNA, VIRAL; GENETIC VECTORS; GENOMIC INSTABILITY; HERPESVIRIDAE; HUMANS; MICE; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; SERIAL PASSAGE; VACCINES; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 75249095378     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.11.056     Document Type: Article

References (52)

1. Moss B., Carroll M.W., Wyatt L.S., Bennink J.R., Hirsch V.M., Goldstein S., et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 397 (1996) 7-13
2. Sutter G., and Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3 3 (2003) 263-271
3. Stickl H., Hochstein-Mintzel V., Mayr A., Huber H.C., Schafer H., and Holzner A. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl.). Dtsch Med Wochenschr 99 47 (1974) 2386-2392
4. Ramirez J.C., Gherardi M.M., and Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation. J Virol 74 2 (2000) 923-933
5. Werner G.T., Jentzsch U., Metzger E., and Simon J. Studies on poxvirus infections in irradiated animals. Arch Virol 64 3 (1980) 247-256
6. Stittelaar K.J., Kuiken T., de Swart R.L., van Amerongen G., Vos H.W., Niesters H.G., et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19 27 (2001) 3700-3709
7. Drexler I., Staib C., and Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?. Curr Opin Biotechnol 15 6 (2004) 506-512
8. Acres B. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2). J BUON 12 Suppl. 1 (2007) S71-S75
9. Sandstrom E., Nilsson C., Hejdeman B., Brave A., Bratt G., Robb M., et al. Broad immunogenicity of a multigene. Multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 198 10 (2008) 1482-1490
10. Rochlitz C., Figlin R., Squiban P., Salzberg M., Pless M., Herrmann R., et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 5 8 (2003) 690-699
11. Peters B.S., Jaoko W., Vardas E., Panayotakopoulos G., Fast P., Schmidt C., et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25 11 (2007) 2120-2127
12. Cosma A., Nagaraj R., Buhler S., Hinkula J., Busch D.H., Sutter G., et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22 1 (2003) 21-29
13. Gilbert S.C., Moorthy V.S., Andrews L., Pathan A.A., McConkey S.J., Vuola J.M., et al. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24 21 (2006) 4554-4561
14. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 93 21 (1996) 11341-11348
15. Chakrabarti S., Sisler J.R., and Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23 6 (1997) 1094-1097
16. Wyatt L.S., Shors S.T., Murphy B.R., and Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14 15 (1996) 1451-1458
17. Gherardi M.M., and Esteban M. Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol 86 Pt 11 (2005) 2925-2936
18. Timm A., Enzinger C., Felder E., and Chaplin P. Genetic stability of recombinant MVA-BN. Vaccine 24 21 (2006) 4618-4621
19. Erfle V., Goebel F.D., Guzman C.A., and Le Grand R. Vaccines based on Nef and on Nef/DeltaV2 Env. Microbes Infect 7 14 (2005) 1400-1404
20. Gomez C.E., Najera J.L., Jimenez E.P., Jimenez V., Wagner R., Graf M., et al. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 25 15 (2007) 2863-2885
21. Wyatt L.S., Belyakov I.M., Earl P.L., Berzofsky J.A., and Moss B. Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology 372 2 (2007) 260-272
22. Wyatt L.S., Earl P.L., Xiao W., Americo J.L., Cotter C.A., Vogt J., et al. Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J Virol 83 14 (2009) 7176-7184
23. Earl P.L., Cotter C., Moss B., Vancott T., Currier J., Eller L.A., et al. Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine 27 42 (2009) 5885-5895
24. Song G.Y., Gibson G., Haq W., Huang E.C., Srivasta T., Hollstein M., et al. An MVA vaccine overcomes tolerance to human p53 in mice and humans. Cancer Immunol Immunother 56 8 (2007) 1193-1205
25. Wang Z., La Rosa C., Lacey S.F., Maas R., Mekhoubad S., Britt W.J., et al. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. J Clin Virol 35 3 (2006) 324-331
26. Yue Y., Wang Z., Abel K., Li J., Strelow L., Mandarino A., et al. Evaluation of recombinant modified Vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques. Med Microbiol Immunol 197 2 (2008) 117-123
27. Wang Z., La Rosa C., Li Z., Ly H., Krishnan A., Martinez J., et al. Vaccine properties of a novel marker gene-free recombinant Modified Vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. Vaccine 25 6 (2007) 1132-1141
28. Wang Z., La Rosa C., Maas R., Ly H., Brewer J., Mekhoubad S., et al. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J Virol 78 8 (2004) 3965-3976
29. Wang Z., Zhou W., Srivastava T., La Rosa C., Mandarino A., Forman S.J., et al. A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector. Virology 377 2 (2008) 379-390
30. Britt W.J., and Auger D. Identification of a 65 000 Da virion envelope protein of human cytomegalovirus. Virus Res 4 1 (1985) 31-36
31. Plachter B., Britt W., Vornhagen R., Stamminger T., and Jahn G. Analysis of proteins encoded by IE regions 1 and 2 of human cytomegalovirus using monoclonal antibodies generated against recombinant antigens. Virology 193 2 (1993) 642-652
32. Schmelz M., Sodeik B., Ericsson M., Wolffe E.J., Shida H., Hiller G., et al. Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J Virol 68 1 (1994) 130-147
33. Lai A.C., and Chu Y. A rapid method for screening vaccinia virus recombinants. Biotechniques 10 5 (1991) 564-565
34. La Rosa C., Wang Z., Brewer J.C., Lacey S.F., Villacres M.C., Sharan R., et al. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood 100 10 (2002) 3681-3689
35. Krishnan A., Wang Z., Srivastava T., Rawal R., Manchanda P., Diamond D.J., et al. A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models. Immunol Lett 120 1-2 (2008) 108-116
36. Wills M.R., Carmichael A.J., Mynard K., Jin X., Weekes M.P., Plachter B., et al. The human CTL response to cytomegalovirus is dominanted by structural protein pp65: frequency, specificity, and T Cell receptor usage of pp65-specific CTL. J Virol 70 11 (1996) 7569-7579
37. Diamond D.J., York J., Sun J., Wright C.L., and Forman S.J. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90 5 (1997) 1751-1767
38. Khan N., Cobbold M., Keenan R., and Moss P.A. Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. J Infect Dis 185 8 (2002) 1025-1034
39. La Rosa C., Krishnan R., Markel S., Schneck J.P., Houghten R., Pinilla C., et al. Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries. Blood 97 6 (2001) 1776-1786
40. La Rosa C., Wang Z., Lacey S.F., Lalimarmo M.M., Krishnan A., Longmate J., et al. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant Modified Vaccinia Ankara. Exp Hematol 34 4 (2006) 497-507
41. Tobery T.W., and Siliciano R.F. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med 185 5 (1997) 909-920
42. Wang Z., La Rosa C., Mekhoubad S., Lacey S.F., Villacres M.C., Markel S., et al. Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood 104 3 (2004) 847-856
43. Britt W.J., and Vugler L. Structural and immunological characterization of the intracellular forms of an abundant 68,000 Mr human cytomegalovirus protein. J Gen Virol 68 Pt 7 (1987) 1897-1907
44. Azuma A., Huang P., Matsuda A., and Plunkett W. 2′-C-cyano-2′-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Mol Pharmacol 59 4 (2001) 725-731
45. Dawson RMC, Elliott DC, Elliott WH, Jones KM. Data for biochemical research. Oxford University Press; 1986. p. 260-1.
46. Wyatt L.S., Earl P.L., Vogt J., Eller L.A., Chandran D., Liu J., et al. Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines. Vaccine 26 4 (2008) 486-493
47. de Haan C.A., Haijema B.J., Boss D., Heuts F.W., and Rottier P.J. Coronaviruses as vectors: stability of foreign gene expression. J Virol 79 20 (2005) 12742-12751
48. Fayzulin R., Scholle F., Petrakova O., Frolov I., and Mason P.W. Evaluation of replicative capacity and genetic stability of West Nile virus replicons using highly efficient packaging cell lines. Virology 351 1 (2006) 196-209
49. Uhde-Holzem K., Fischer R., and Commandeur U. Genetic stability of recombinant potato virus × virus vectors presenting foreign epitopes. Arch Virol 152 4 (2007) 805-811
50. Kidokoro M., Tashiro M., and Shida H. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc Natl Acad Sci USA 102 11 (2005) 4152-4157
51. Butrapet S., Kinney R.M., and Huang C.Y. Determining genetic stabilities of chimeric dengue vaccine candidates based on dengue 2 PDK-53 virus by sequencing and quantitative TaqMAMA. J Virol Methods 131 1 (2006) 1-9
52. Stittelaar K.J., Wyatt L.S., de Swart R.L., Vos H.W., Groen J., van Amerongen G., et al. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol 74 9 (2000) 4236-4243